A recent analysis published in Obstetrics & Gynecology considers screening for hepatitis B antibodies and vaccinating pregnant women without immunity to be a cost-effective health measure.
Although vaccination is not routine during pregnancy, guidelines from the American College of Obstetricians and Gynecologists recommend screening and vaccinating at-risk women for hepatitis B during pregnancy.
In their recent study, Dr. Prabhu and her colleagues determined how universal hepatitis B surface antibody screening and vaccination for hepatitis B affected factors like cost, cost-effectiveness, and outcomes. They included hepatitis B virus cases and long-term problems associated with hepatitis B infection, like hepatocellular carcinoma, decompensated cirrhosis, liver transplant, and death.Â
They found the universal screening and vaccination program cost-effective, with fewer cases of hepatitis B, deaths, decompensated cirrhosis cases, and liver transplants in their model. They also found an incremental cost-effectiveness ratio of $1,890 per quality-adjusted life-years (QALYs) and the total increased lifetime cohort cost as $13,841,889. This model holds true even in scenarios with a high level of hepatitis B immunity and no presence of at-risk women in the model.
If real-world studies show that a hepatitis B universal screening and vaccination program is cost-effective, guidelines must reconsider the population to be screened and vaccinated.Â
Under guidelines that direct all pregnant women to be screened and vaccinated for hepatitis B regardless of risk, conducting one extra blood test, among many other blood tests at the first prenatal visit, is no harm.
Thus, Clinicians must consider adding hepatitis B screening to prenatal care, given that ACOG recently released routine hepatitis C screening for pregnant women as a practice advisory.
Craven J. Universal hepatitis B screening, vaccination deemed cost-effective for pregnant women. MDEdge. February 10, 2022. https://www.mdedge.com/obgyn/article/251664/preventive-care/universal-hepatitis-b-screening-vaccination-deemed-cost?reg=1
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
Please login to comment on this article